Report Detail
Global Xeligekimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032
- RnM4706241 |
- 09 June, 2026 |
- Global |
- 82 Pages |
- GIR |
- Pharma & Healthcare
According to our (Global Info Research) latest study, the global Xeligekimab market size was valued at US$ 143 million in 2025 and is forecast to a readjusted size of US$ 692 million by 2032 with a CAGR of 8.3% during review period.
In 2025, global Xeligekimab production reached approximately 150,000 vials.Sereliximab is a monoclonal antibody drug that is currently in the research or clinical development stage. It works by targeting specific immune-related receptors or inflammatory pathways to regulate the body’s immune response, and is therefore used in the treatment of autoimmune diseases, inflammatory diseases, and other immune-related disorders. As an important type of biologic therapy, Sereliximab is characterized by high target specificity, a well-defined mechanism of action, and potentially manageable side effects, giving it promising applications in precision medicine and immunotherapy. With the continuous advancement of global biotechnology and ongoing development of innovative antibody drugs, Sereliximab has attracted increasing attention in terms of clinical indication expansion and future commercialization potential.
As one of the monoclonal antibody drugs that has attracted attention in the field of immunotherapy in recent years, Sereliximab is still in a relatively early stage of market development. At present, publicly available global market data, sales scale, and production statistics remain limited, making the overall market a relatively emerging niche segment without mature data support. With the continuous growth in demand for treatments for autoimmune and inflammatory diseases, the biologics market continues to expand, providing potential development opportunities for the future commercialization of Sereliximab. Meanwhile, increasing investment by global pharmaceutical companies in innovative antibody drug research and development is also promoting active progress in clinical studies and indication expansion for related products. Future market growth will mainly depend on clinical trial progress, indication approvals, medical insurance coverage capabilities, and the competitive landscape of similar targeted therapies. Overall, the Sereliximab market is currently still dominated by the research, development, and early commercialization stage, with limited short-term market size but certain long-term growth potential.
This report is a detailed and comprehensive analysis for global Xeligekimab market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Xeligekimab market size and forecasts, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Xeligekimab market size and forecasts by region and country, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Xeligekimab market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (Units), and average selling prices (US$/Unit), 2021-2032
Global Xeligekimab market shares of main players, shipments in revenue ($ Million), sales quantity (Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Xeligekimab
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Xeligekimab market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Chongqing Genrix Biopharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Xeligekimab market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
100 mg / 1 ml
200 mg / 1 ml
Market segment by Production Technology
Innovator
Generic
Market segment by Combination Medication
Combination with Nonsteroidal Anti-Inflammatory Drugs
Combination with Topical Preparations
Market segment by Sales Channels
Hospitals
Retail
Online
Market segment by Application
Autoimmune Diseases
Psoriatic Arthritis
Spondyloarthritis
Others
Major players covered
Chongqing Genrix Biopharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Xeligekimab product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Xeligekimab, with price, sales quantity, revenue, and global market share of Xeligekimab from 2021 to 2026.
Chapter 3, the Xeligekimab competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Xeligekimab breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Xeligekimab market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Xeligekimab.
Chapter 14 and 15, to describe Xeligekimab sales channel, distributors, customers, research findings and conclusion.
1 Market Overview
- 1.1 Product Overview and Scope
- 1.2 Market Estimation Caveats and Base Year
- 1.3 Market Analysis by Type
- 1.3.1 Overview: Global Xeligekimab Consumption Value by Type: 2021 Versus 2025 Versus 2032
- 1.3.2 100 mg / 1 ml
- 1.3.3 200 mg / 1 ml
- 1.4 Market Analysis by Production Technology
- 1.4.1 Overview: Global Xeligekimab Consumption Value by Production Technology: 2021 Versus 2025 Versus 2032
- 1.4.2 Innovator
- 1.4.3 Generic
- 1.5 Market Analysis by Combination Medication
- 1.5.1 Overview: Global Xeligekimab Consumption Value by Combination Medication: 2021 Versus 2025 Versus 2032
- 1.5.2 Combination with Nonsteroidal Anti-Inflammatory Drugs
- 1.5.3 Combination with Topical Preparations
- 1.6 Market Analysis by Sales Channels
- 1.6.1 Overview: Global Xeligekimab Consumption Value by Sales Channels: 2021 Versus 2025 Versus 2032
- 1.6.2 Hospitals
- 1.6.3 Retail
- 1.6.4 Online
- 1.7 Market Analysis by Application
- 1.7.1 Overview: Global Xeligekimab Consumption Value by Application: 2021 Versus 2025 Versus 2032
- 1.7.2 Autoimmune Diseases
- 1.7.3 Psoriatic Arthritis
- 1.7.4 Spondyloarthritis
- 1.7.5 Others
- 1.8 Global Xeligekimab Market Size & Forecast
- 1.8.1 Global Xeligekimab Consumption Value (2021 & 2025 & 2032)
- 1.8.2 Global Xeligekimab Sales Quantity (2021-2032)
- 1.8.3 Global Xeligekimab Average Price (2021-2032)
2 Manufacturers Profiles
- 2.1 Chongqing Genrix Biopharmaceutical
- 2.1.1 Chongqing Genrix Biopharmaceutical Details
- 2.1.2 Chongqing Genrix Biopharmaceutical Major Business
- 2.1.3 Chongqing Genrix Biopharmaceutical Xeligekimab Product and Services
- 2.1.4 Chongqing Genrix Biopharmaceutical Xeligekimab Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Chongqing Genrix Biopharmaceutical Recent Developments/Updates
3 Competitive Environment: Xeligekimab by Manufacturer
- 3.1 Global Xeligekimab Sales Quantity by Manufacturer (2021-2026)
- 3.2 Global Xeligekimab Revenue by Manufacturer (2021-2026)
- 3.3 Global Xeligekimab Average Price by Manufacturer (2021-2026)
- 3.4 Market Share Analysis (2025)
- 3.4.1 Producer Shipments of Xeligekimab by Manufacturer Revenue ($MM) and Market Share (%): 2025
- 3.4.2 Top 3 Xeligekimab Manufacturer Market Share in 2025
- 3.4.3 Top 6 Xeligekimab Manufacturer Market Share in 2025
- 3.5 Xeligekimab Market: Overall Company Footprint Analysis
- 3.5.1 Xeligekimab Market: Region Footprint
- 3.5.2 Xeligekimab Market: Company Product Type Footprint
- 3.5.3 Xeligekimab Market: Company Product Application Footprint
- 3.6 New Market Entrants and Barriers to Market Entry
- 3.7 Mergers, Acquisition, Agreements, and Collaborations
4 Consumption Analysis by Region
- 4.1 Global Xeligekimab Market Size by Region
- 4.1.1 Global Xeligekimab Sales Quantity by Region (2021-2032)
- 4.1.2 Global Xeligekimab Consumption Value by Region (2021-2032)
- 4.1.3 Global Xeligekimab Average Price by Region (2021-2032)
- 4.2 North America Xeligekimab Consumption Value (2021-2032)
- 4.3 Europe Xeligekimab Consumption Value (2021-2032)
- 4.4 Asia-Pacific Xeligekimab Consumption Value (2021-2032)
- 4.5 South America Xeligekimab Consumption Value (2021-2032)
- 4.6 Middle East & Africa Xeligekimab Consumption Value (2021-2032)
5 Market Segment by Type
- 5.1 Global Xeligekimab Sales Quantity by Type (2021-2032)
- 5.2 Global Xeligekimab Consumption Value by Type (2021-2032)
- 5.3 Global Xeligekimab Average Price by Type (2021-2032)
6 Market Segment by Application
- 6.1 Global Xeligekimab Sales Quantity by Application (2021-2032)
- 6.2 Global Xeligekimab Consumption Value by Application (2021-2032)
- 6.3 Global Xeligekimab Average Price by Application (2021-2032)
7 North America
- 7.1 North America Xeligekimab Sales Quantity by Type (2021-2032)
- 7.2 North America Xeligekimab Sales Quantity by Application (2021-2032)
- 7.3 North America Xeligekimab Market Size by Country
- 7.3.1 North America Xeligekimab Sales Quantity by Country (2021-2032)
- 7.3.2 North America Xeligekimab Consumption Value by Country (2021-2032)
- 7.3.3 United States Market Size and Forecast (2021-2032)
- 7.3.4 Canada Market Size and Forecast (2021-2032)
- 7.3.5 Mexico Market Size and Forecast (2021-2032)
8 Europe
- 8.1 Europe Xeligekimab Sales Quantity by Type (2021-2032)
- 8.2 Europe Xeligekimab Sales Quantity by Application (2021-2032)
- 8.3 Europe Xeligekimab Market Size by Country
- 8.3.1 Europe Xeligekimab Sales Quantity by Country (2021-2032)
- 8.3.2 Europe Xeligekimab Consumption Value by Country (2021-2032)
- 8.3.3 Germany Market Size and Forecast (2021-2032)
- 8.3.4 France Market Size and Forecast (2021-2032)
- 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
- 8.3.6 Russia Market Size and Forecast (2021-2032)
- 8.3.7 Italy Market Size and Forecast (2021-2032)
9 Asia-Pacific
- 9.1 Asia-Pacific Xeligekimab Sales Quantity by Type (2021-2032)
- 9.2 Asia-Pacific Xeligekimab Sales Quantity by Application (2021-2032)
- 9.3 Asia-Pacific Xeligekimab Market Size by Region
- 9.3.1 Asia-Pacific Xeligekimab Sales Quantity by Region (2021-2032)
- 9.3.2 Asia-Pacific Xeligekimab Consumption Value by Region (2021-2032)
- 9.3.3 China Market Size and Forecast (2021-2032)
- 9.3.4 Japan Market Size and Forecast (2021-2032)
- 9.3.5 South Korea Market Size and Forecast (2021-2032)
- 9.3.6 India Market Size and Forecast (2021-2032)
- 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
- 9.3.8 Australia Market Size and Forecast (2021-2032)
10 South America
- 10.1 South America Xeligekimab Sales Quantity by Type (2021-2032)
- 10.2 South America Xeligekimab Sales Quantity by Application (2021-2032)
- 10.3 South America Xeligekimab Market Size by Country
- 10.3.1 South America Xeligekimab Sales Quantity by Country (2021-2032)
- 10.3.2 South America Xeligekimab Consumption Value by Country (2021-2032)
- 10.3.3 Brazil Market Size and Forecast (2021-2032)
- 10.3.4 Argentina Market Size and Forecast (2021-2032)
11 Middle East & Africa
- 11.1 Middle East & Africa Xeligekimab Sales Quantity by Type (2021-2032)
- 11.2 Middle East & Africa Xeligekimab Sales Quantity by Application (2021-2032)
- 11.3 Middle East & Africa Xeligekimab Market Size by Country
- 11.3.1 Middle East & Africa Xeligekimab Sales Quantity by Country (2021-2032)
- 11.3.2 Middle East & Africa Xeligekimab Consumption Value by Country (2021-2032)
- 11.3.3 Turkey Market Size and Forecast (2021-2032)
- 11.3.4 Egypt Market Size and Forecast (2021-2032)
- 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
- 11.3.6 South Africa Market Size and Forecast (2021-2032)
12 Market Dynamics
- 12.1 Xeligekimab Market Drivers
- 12.2 Xeligekimab Market Restraints
- 12.3 Xeligekimab Trends Analysis
- 12.4 Porters Five Forces Analysis
- 12.4.1 Threat of New Entrants
- 12.4.2 Bargaining Power of Suppliers
- 12.4.3 Bargaining Power of Buyers
- 12.4.4 Threat of Substitutes
- 12.4.5 Competitive Rivalry
13 Raw Material and Industry Chain
- 13.1 Raw Material of Xeligekimab and Key Manufacturers
- 13.2 Manufacturing Costs Percentage of Xeligekimab
- 13.3 Xeligekimab Production Process
- 13.4 Industry Value Chain Analysis
14 Shipments by Distribution Channel
- 14.1 Sales Channel
- 14.1.1 Direct to End-User
- 14.1.2 Distributors
- 14.2 Xeligekimab Typical Distributors
- 14.3 Xeligekimab Typical Customers
15 Research Findings and Conclusion
16 Appendix
- 16.1 Methodology
- 16.2 Research Process and Data Source
Summary:
Get latest Market Research Reports on Xeligekimab. Industry analysis & Market Report on Xeligekimab is a syndicated market report, published as Global Xeligekimab Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Xeligekimab market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.
REPORT YOU MIGHT BE INTERESTED
Related Reports
Reason to Buy
Reports and Markets
Contact Us
+1-352-353-0818 (US)Newsletter
KEEP UP TO DATE ON ALL THE LATEST REPORTS
